---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-26-000016"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-07-30T20:05:37+00:00"
generated_at: "2026-07-30T20:07:10.373458+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q2 net income $83.5M, raises FY product revenue guidance to $850-950M

## Summary
- Q2 total revenue $361M (product $239M) includes $50M Novartis milestone; net income $83.5M vs net loss $64.8M YoY.
- FY 2026 product revenue guidance raised to $850-950M (from $750-850M); total revenue guidance raised to $1.18-1.28B.
- Sephience Q2 revenue $151M (+21% QoQ); 1,647 patients on therapy; Translarna $42.2M, Emflaza $24.6M, Evrysdi royalty $71.1M.
- Issued $550M senior convertible notes due 2031 at 0% coupon, 40% conversion premium; repurchased majority of 1.5% notes due 2026. Cash $2.23B.
- Pipeline: PTC303 (MSH3) targeting Huntington's, clinic entry 2027; PTC612 (NLRP3) Phase 1 initiated; vatiquinone PROVE-FA study Q3 2026; votoplam PIVOT-HD 24-month results showed 52% disease slowing.

## SEC filing metadata
- accession: 0001070081-26-000016
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-07-30T20:05:37+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/0001070081-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000016/tmb-20260728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-26-000016
- JSON: https://secwatch.observer/filing/0001070081-26-000016.json
- Plain text: https://secwatch.observer/filing/0001070081-26-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.